World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Check for updates

Evolutionary Trajectories in Phytopharmaceutical Drug Development: From Ethnopharmacology to Polypharmacology

Bindu Alex *

Department of Botany, Mar Ivanios College, Nalanchira, Thiruvananthapuram, Kerala-695015.

World Journal of Biology Pharmacy and Health Sciences, 2025, 23(03), 001-005

Publication history: Received on 22 July 2025; revised on 27 August 2025; accepted on 01 September 2025

Article DOI: https://doi.org/10.30574/wjbphs.2025.23.3.0795

Abstract

The development of drugs from plants (phytopharmaceuticals) has evolved from traditional use to a sophisticated, evidence-based scientific discipline. This review delineates the critical evolutionary pathway from ethnopharmacology—the study of traditional medicinal uses of plants—to the modern paradigm of polypharmacology, which involves multi-target therapies. While ethnopharmacology provides a time-tested foundation for drug discovery by identifying biologically active plant species, it often focuses on single-component isolation. However, the therapeutic efficacy of many plant extracts is attributable to the synergistic actions of multiple constituents acting on multiple biological targets, a concept central to polypharmacology. This paper reviews these complementary approaches, highlighting how traditional knowledge, when interrogated with modern analytical and pharmacological techniques, can lead to the development of novel multi-target phytopharmaceuticals. We discuss the methodologies involved, present key examples, and address the challenges and future perspectives in this integrative field.

Keywords: Phytopharmaceuticals; Ethnopharmacology; Polypharmacology; Synergy; Medicinal Plants; Multi-target Therapeutics; Natural Products

1. Introduction

Plants have been the cornerstone of traditional medicine systems for millennia, forming the basis of modern pharmacology. Approximately 40% of modern clinical drugs are either natural products or their derivatives, with a significant portion originating from ethnobotanical leads [1]. The journey from a medicinal plant to a marketable drug is complex, requiring a multidisciplinary approach.

Historically, drug discovery from plants followed a linear path: ethnopharmacological observation → bioactivity-guided fractionation → isolation of a single active compound → development into a drug (e.g., morphine, quinine, paclitaxel). This "silver bullet" model, while successful, often overlooks the inherent complexity of plant extracts. Many botanicals exert their therapeutic effects not through a single potent molecule, but through the combined action of multiple compounds working in concert—a phenomenon known as synergy [2].

This realization has catalyzed a paradigm shift towards polypharmacology—the design or use of pharmaceutical agents that act on multiple molecular targets simultaneously. This approach is particularly relevant for complex multifactorial diseases like cancer, metabolic disorders, and neurodegenerative conditions [3]. Consequently, phytopharmaceutical development is increasingly embracing a holistic model that respects the integrity of multi-component extracts while rigorously validating their multi-target mechanisms, effectively bridging the ancient wisdom of ethnopharmacology with the cutting-edge science of polypharmacology. This review explores this evolutionary trajectory, its methodologies, applications, and future directions.

* Corresponding author: Bindu Alex.

2. Materials and Methods

This review was conducted through a systematic search of major scientific databases, including PubMed, Scopus, Web of Science, and Google Scholar. The search strategy employed a combination of keywords and MeSH terms such as "phytopharmaceutical development," "ethnopharmacology," "polypharmacology," "plant extract synergy," "multi-target therapeutics," "medicinal plants," and "network pharmacology."

- **Inclusion Criteria:** Peer-reviewed original research articles, review papers, and meta-analyses published primarily within the last decade (2014-2024) were prioritized. Seminal older publications were included for foundational concepts.
- **Exclusion Criteria:** Non-English articles, articles without full-text availability, and studies with insufficient methodological detail were excluded.
- **Data Extraction and Synthesis:** Relevant data on plant species, traditional use, isolated compounds, pharmacological models, mechanisms of action, and evidence of polypharmacology or synergy were extracted. The information was synthesized into a narrative review format to provide a comprehensive overview of the field.

2.1. The Ethnopharmacological Approach: A Foundational Filter

Ethnopharmacology is the scientific study of indigenous biological materials and their biological activities based on the traditional uses of local people [4]. It serves as a powerful pre-screen, significantly increasing the probability of discovering bioactive compounds by focusing on plants with a history of human use.

3. Methodology

3.1. Field Study & Documentation

Collaboration with traditional healers and local communities to document plant species, parts used, preparation methods (decoction, infusion, etc.), and ailments treated [5].

- **Authentication:** Botanical identification and voucher specimen deposition in herbariums.
- **Extraction:** Preparation of crude extracts using solvents of varying polarity (e.g., water, ethanol, methanol) to mimic traditional preparations.
- ***In Vitro* and *In Vivo* Bioassays:** Screening extracts for relevant biological activities (e.g., antimicrobial, anti-inflammatory, anticancer) using validated models.

3.2. Limitations

Ethnopharmacology identifies *that* a plant works but not always *how* or *why*. It can be confounded by placebo effects, cultural beliefs, and misidentification. Furthermore, it often points to a single plant for a single disease, which is a simplification of its potential polypharmacological nature.

3.3. The Polypharmacological Approach: Embracing Complexity

Polypharmacology directly challenges the traditional one-drug-one-target paradigm by positing that complex diseases are best treated through the modulation of entire networks of targets rather than a single protein [3]. In this context, plant extracts are inherently polypharmacological, as they consist of dozens to hundreds of compounds with diverse biological activities. Their therapeutic potential is largely driven by two key concepts: synergy, where the interaction of multiple compounds produces a total effect greater than the sum of their individual effects, often allowing for lower doses of individual components and reduced toxicity [2]; and multi-target effects, where different compounds within an extract act simultaneously on various nodes of a disease-associated pathway. Validating these complex mechanisms requires sophisticated methodological tools, including omics technologies (such as transcriptomics, proteomics, and metabolomics) to profile the global biological changes induced by an extract and reveal affected pathways [6]; network pharmacology, a computational approach that maps the intricate relationships between plant compounds, their protein targets, and disease pathways into a comprehensive "compound-target-disease" network [7]; and advanced bioassays, like high-content screening, which are designed to capture these complex, multi-target phenotypic responses more effectively than single-target assays.

Table 1 Contrasting the Single-Target and Polypharmacological Paradigms in Phytopharmaceuticals

Feature	Single-Target / Isolated Compound Approach	Polypharmacological / Whole Extract Approach
Philosophy	"Silver bullet"	"Shotgun" or "Systems" approach
Basis	Isolate and optimize the most active single compound	Utilize the natural combination of compounds
Mechanism	High affinity binding to a single target	Moderate modulation of multiple targets
Advantages	Well-defined mechanism; easier pharmacokinetic and patent profiling	Potential for synergy; lower risk of drug resistance; better for complex diseases
Disadvantages	Risk of off-target effects; susceptible to drug resistance; may lose efficacy of full extract	Complex mechanism; standardization challenges; intellectual property issues
Example	Paclitaxel (from *Taxus brevifolia*) for cancer	Standardized *Hypericum perforatum* (St. John's Wort) extract for mild-moderate depression

3.4. Integrating Ethnopharmacology and Polypharmacology: Case Studies

3.4.1. Artemisia annua (Qinghao) and Malaria:

- **Ethnopharmacology:** Used in Traditional Chinese Medicine (TCM) for fevers and chills.
- **Single Compound:** Artemisinin was isolated as the primary antimalarial compound, a Nobel Prize-winning discovery [8].
- **Polypharmacology:** Recent evidence shows that the whole plant extract has superior efficacy and reduces artemisinin resistance potential compared to pure artemisinin, likely due to the presence of flavonoids and other compounds that enhance bioavailability and provide complementary antioxidant effects [9].

3.4.2. Curcuma longa (Turmeric) and Inflammation:

- **Ethnopharmacology:** A cornerstone of Ayurvedic medicine for inflammatory conditions.
- **Single Compound:** Curcumin is the most studied anti-inflammatory compound.
- **Polypharmacology:** Curcumin alone has poor bioavailability. The whole turmeric extract, containing turmerones and other constituents, exhibits enhanced absorption and broader anti-inflammatory activity through modulation of NF-κB, COX-2, LOX, and other inflammatory mediators simultaneously—a true polypharmacological profile [10].

3.4.3. Cannabis sativa and Neurological Disorders:

- **Ethnopharmacology:** Historical use for pain and spasms.
- **Single Compound:** THC and CBD isolated as major active cannabinoids.
- **Polypharmacology:** The "entourage effect" describes how THC, CBD, terpenes (e.g., myrcene, limonene), and flavonoids work synergistically to modulate the endocannabinoid system and other targets, resulting in enhanced therapeutic effects and a mitigated side-effect profile compared to isolated THC [11].

Table 2 Examples of Plant Extracts with Evidence of Polypharmacological Mechanisms

Plant (Extract)	Traditional Use	Key Phytochemical Classes	Polypharmacological Targets & Effects	Reference
Ginkgo biloba (EGb 761)	Memory enhancement	Flavonoids, Terpene lactones (ginkgolides)	Antioxidant, inhibits Aβ aggregation, modulates cholinergic system, improves cerebral blood flow	[12]
Hypericum perforatum (St. John's Wort)	Depression, wounds	Naphthodianthrones (hypericin), Phloroglucinols (hyperforin)	Inhibits synaptic reuptake of serotonin, dopamine, norepinephrine; MAO-A inhibition (disputed)	[13]

Salix alba (Willow Bark)	Pain, fever	Phenolic glycosides (salicin)	Salicin metabolized to salicylic acid; COX-1/2 inhibition; antioxidant and anti-inflammatory polyphenols provide additive effects	[14]
Zingiber officinale (Ginger)	Nausea, inflammation	Gingerols, Shogaols	5-HT3 receptor antagonism (anti-emetic), COX/LOX inhibition (anti-inflammatory), antioxidant	[15]

3.5. Challenges and Future Perspectives

The advancement of plant-based polypharmacology faces several significant challenges. A primary hurdle is standardization, as ensuring batch-to-batch consistency for complex extracts requires moving beyond quality control based on single marker compounds to methods that profile overall biological activity [16]. Furthermore, the mechanistic elucidation of how each constituent contributes to the overall effect remains immensely complex. From a development perspective, there are regulatory hurdles; while agencies like the FDA and EMA have frameworks for botanical drugs, they still demand rigorous proof of quality, safety, and efficacy, which is inherently more complicated for multi-component agents [17]. Additionally, securing intellectual property for inventions based on traditional knowledge and naturally occurring mixtures presents a persistent challenge.

Looking to the future, overcoming these obstacles will rely on several key advancements. Advanced analytics, including techniques like LC-MS/MS, NMR metabolomics, and DNA barcoding, will be essential for ensuring authenticity and achieving detailed phytochemical characterization [18]. AI and machine learning will be crucial for deciphering complex interactions, as these tools can analyze large omics datasets, predict synergistic relationships, and help design optimized polypharmacological formulations [19]. Ultimately, clinical validation through well-designed randomized controlled trials (RCTs) that compare whole extracts to both isolated compounds and standard-of-care treatments is essential to demonstrate efficacy [20]. Finally, establishing ethical and sustainable sourcing practices is critical to preserve biodiversity and ensure that the development of these medicines respects the traditional knowledge from which they often originate.

4. Conclusion

The development of phytopharmaceuticals is undergoing a significant transformation. The linear path from ethnopharmacology to a single isolated drug is being supplemented by a more holistic, integrative approach. Ethnopharmacology remains an invaluable starting point, offering pre-validated, culturally relevant leads. By applying the principles of polypharmacology and modern systems biology tools, researchers can now decode the complex mechanisms underlying the efficacy of whole plant medicines. This synergy between ancient wisdom and contemporary science promises to unlock a new generation of effective, safe, and multi-targeted phytopharmaceuticals for addressing some of the most challenging multifactorial diseases of our time.

Compliance with ethical standards

Acknowledgment

The author is grateful to Principal, Mar Ivanios College (Autonomous) for providing necessary facilities.

References

[1] Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803.

[2] Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2-3):97-110.

[3] Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57(19):7874-87.

[4] Heinrich M, Jäger AK. Ethnopharmacology. West Sussex: John Wiley & Sons; 2015.

[5] Weckerle CS, de Boer HJ, Puri RK, van Andel T, Bussmann RW, Leonti M. Recommended standards for conducting and reporting ethnopharmacological field studies. J Ethnopharmacol. 2018;210:125-32.

[6] Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets. 2011;12(1):122-32.

[7] Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-90.

[8] Tu Y. Artemisinin—A Gift from Traditional Chinese Medicine to the World (Nobel Lecture). Angew Chem Int Ed Engl. 2016;55(35):10210-26.

[9] Elfawal MA, Towler MJ, Reich NG, Golenbock D, Weathers PJ, Rich SM. Dried whole plant Artemisia annua as an antimalarial therapy. PLoS One. 2015;10(12):e0144856.

[10] Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods. 2017;6(10):92.

[11] Russo EB. The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No "Strain," No Gain. Front Plant Sci. 2019;9:1969.

[12] Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. Neurotherapeutics. 2019;16(3):666-74.

[13] Apaydin EA, Maher AR, Shanman R, Booth MS, Miles JN, Sorbero ME, et al. A systematic review of St. John's wort for major depressive disorder. Syst Rev. 2016;5(1):148.

[14] Shara M, Stohs SJ. Efficacy and Safety of White Willow Bark (Salix alba) Extracts. Phytother Res. 2015;29(8):1112-6.

[15] Anh NH, Kim SJ, Long NP, Min JE, Yoon YC, Lee EG, et al. Ginger on Human Health: A Comprehensive Systematic Review of 109 Randomized Controlled Trials. Nutrients. 2020;12(1):157.

[16] Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect. 2001;109 Suppl 1:69-75.

[17] U.S. Food and Drug Administration. Botanical Drug Development Guidance for Industry. Silver Spring, MD: U.S. Department of Health and Human Services; 2016.

[18] Wolfender JL, Litaudon M, Touboul D, Queiroz EF. Innovative omics-based approaches for prioritisation and targeted isolation of natural products – new strategies for drug discovery. Nat Prod Rep. 2019;36(6):855-68.

[19] Zeng X, Zhang P, He W, Qin C, Chen S, Tao L, et al. NPASS: natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Res. 2018;46(D1):D1217-D1222.

[20] Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2016;21(5):559.